Comparative Pharmacology
Head-to-head clinical analysis: BREYNA versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREYNA versus VOLNEA.
BREYNA vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREYNA is a contraceptive vaginal ring that releases ethinyl estradiol and etonogestrel. Etonogestrel is a progestogen that inhibits ovulation by suppressing gonadotropin release. Ethinyl estradiol enhances the contraceptive effect by stabilizing the endometrium and increasing cervical mucus viscosity.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
1 mg subcutaneously twice daily
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Terminal elimination half-life is 12 hours; in patients with moderate to severe renal impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Primarily renal excretion of unchanged drug (approximately 70%) and biliary/fecal elimination (approximately 30%)
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive